Completion and toxicity of induction chemotherapy for metastatic testicular cancer: An updated evaluation of Japanese patients

Koji Kawai, Satoshi Ando, Shiro Hinotsu, Takehiro Oikawa, Noritoshi Sekido, Naoto Miyanaga, Toru Shimazui, Hideyuki Akaza

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Combination of bleomycin, etoposide and cisplatin (BEP) remains the standard chemotherapy for testicular cancer. Since the development of BEP in the 1980s, there has been a considerable advance in supportive therapies, such as granulocyte colony-stimulating-factor and 5-HT3 antagonists. Therefore, we re-evaluated the completion and toxicity of BEP combined with modern supportive care. Methods: The medical records of all 42 testicular cancer patients who received induction chemotherapy at Tsukuba University Hospital were reviewed. Toxicities during the induction chemotherapy were graded according to the Japanese CTCAE v3.0. Results: Dose reduction was needed in only three patients. The subsequent chemotherapy was started at the planned 3 week interval or within 3 days of postponement in 89% of the treatment cycles. The average relative dose intensity (RDI) of bleomycin was 0.95, while that for etoposide and cisplatin was 0.97. There was no death due to toxicity. The most frequent toxicity was leukopenia (grade 3 in 44% and grade 4 in 55%). Post-chemotherapy diffusion capacity was significantly decreased in 30% of patients. Two patients developed bleomycin-induced pneumonitis, but recovered successfully. Sixteen patients received second line or salvage chemotherapy after BEP, subsequently. The overall 5 year cause-specific survival rate was 85%. Conclusion: BEP with high RDIs is acceptable if combined with modern supportive care, with acceptable toxicity profile in most patients.

Original languageEnglish
Pages (from-to)425-431
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume36
Issue number7
DOIs
Publication statusPublished - Jul 2006
Externally publishedYes

Fingerprint

Induction Chemotherapy
Bleomycin
Testicular Neoplasms
Etoposide
Cisplatin
Drug Therapy
Serotonin 5-HT3 Receptor Antagonists
Leukopenia
Granulocyte Colony-Stimulating Factor
Medical Records
Pneumonia
Survival Rate
Therapeutics

Keywords

  • BEP
  • IGCCCG classification
  • Testicular cancer
  • Toxicity

ASJC Scopus subject areas

  • Oncology

Cite this

Completion and toxicity of induction chemotherapy for metastatic testicular cancer : An updated evaluation of Japanese patients. / Kawai, Koji; Ando, Satoshi; Hinotsu, Shiro; Oikawa, Takehiro; Sekido, Noritoshi; Miyanaga, Naoto; Shimazui, Toru; Akaza, Hideyuki.

In: Japanese Journal of Clinical Oncology, Vol. 36, No. 7, 07.2006, p. 425-431.

Research output: Contribution to journalArticle

Kawai, Koji ; Ando, Satoshi ; Hinotsu, Shiro ; Oikawa, Takehiro ; Sekido, Noritoshi ; Miyanaga, Naoto ; Shimazui, Toru ; Akaza, Hideyuki. / Completion and toxicity of induction chemotherapy for metastatic testicular cancer : An updated evaluation of Japanese patients. In: Japanese Journal of Clinical Oncology. 2006 ; Vol. 36, No. 7. pp. 425-431.
@article{80f7227ce9dc4f7b892f4dcc1975011a,
title = "Completion and toxicity of induction chemotherapy for metastatic testicular cancer: An updated evaluation of Japanese patients",
abstract = "Background: Combination of bleomycin, etoposide and cisplatin (BEP) remains the standard chemotherapy for testicular cancer. Since the development of BEP in the 1980s, there has been a considerable advance in supportive therapies, such as granulocyte colony-stimulating-factor and 5-HT3 antagonists. Therefore, we re-evaluated the completion and toxicity of BEP combined with modern supportive care. Methods: The medical records of all 42 testicular cancer patients who received induction chemotherapy at Tsukuba University Hospital were reviewed. Toxicities during the induction chemotherapy were graded according to the Japanese CTCAE v3.0. Results: Dose reduction was needed in only three patients. The subsequent chemotherapy was started at the planned 3 week interval or within 3 days of postponement in 89{\%} of the treatment cycles. The average relative dose intensity (RDI) of bleomycin was 0.95, while that for etoposide and cisplatin was 0.97. There was no death due to toxicity. The most frequent toxicity was leukopenia (grade 3 in 44{\%} and grade 4 in 55{\%}). Post-chemotherapy diffusion capacity was significantly decreased in 30{\%} of patients. Two patients developed bleomycin-induced pneumonitis, but recovered successfully. Sixteen patients received second line or salvage chemotherapy after BEP, subsequently. The overall 5 year cause-specific survival rate was 85{\%}. Conclusion: BEP with high RDIs is acceptable if combined with modern supportive care, with acceptable toxicity profile in most patients.",
keywords = "BEP, IGCCCG classification, Testicular cancer, Toxicity",
author = "Koji Kawai and Satoshi Ando and Shiro Hinotsu and Takehiro Oikawa and Noritoshi Sekido and Naoto Miyanaga and Toru Shimazui and Hideyuki Akaza",
year = "2006",
month = "7",
doi = "10.1093/jjco/hyl053",
language = "English",
volume = "36",
pages = "425--431",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Completion and toxicity of induction chemotherapy for metastatic testicular cancer

T2 - An updated evaluation of Japanese patients

AU - Kawai, Koji

AU - Ando, Satoshi

AU - Hinotsu, Shiro

AU - Oikawa, Takehiro

AU - Sekido, Noritoshi

AU - Miyanaga, Naoto

AU - Shimazui, Toru

AU - Akaza, Hideyuki

PY - 2006/7

Y1 - 2006/7

N2 - Background: Combination of bleomycin, etoposide and cisplatin (BEP) remains the standard chemotherapy for testicular cancer. Since the development of BEP in the 1980s, there has been a considerable advance in supportive therapies, such as granulocyte colony-stimulating-factor and 5-HT3 antagonists. Therefore, we re-evaluated the completion and toxicity of BEP combined with modern supportive care. Methods: The medical records of all 42 testicular cancer patients who received induction chemotherapy at Tsukuba University Hospital were reviewed. Toxicities during the induction chemotherapy were graded according to the Japanese CTCAE v3.0. Results: Dose reduction was needed in only three patients. The subsequent chemotherapy was started at the planned 3 week interval or within 3 days of postponement in 89% of the treatment cycles. The average relative dose intensity (RDI) of bleomycin was 0.95, while that for etoposide and cisplatin was 0.97. There was no death due to toxicity. The most frequent toxicity was leukopenia (grade 3 in 44% and grade 4 in 55%). Post-chemotherapy diffusion capacity was significantly decreased in 30% of patients. Two patients developed bleomycin-induced pneumonitis, but recovered successfully. Sixteen patients received second line or salvage chemotherapy after BEP, subsequently. The overall 5 year cause-specific survival rate was 85%. Conclusion: BEP with high RDIs is acceptable if combined with modern supportive care, with acceptable toxicity profile in most patients.

AB - Background: Combination of bleomycin, etoposide and cisplatin (BEP) remains the standard chemotherapy for testicular cancer. Since the development of BEP in the 1980s, there has been a considerable advance in supportive therapies, such as granulocyte colony-stimulating-factor and 5-HT3 antagonists. Therefore, we re-evaluated the completion and toxicity of BEP combined with modern supportive care. Methods: The medical records of all 42 testicular cancer patients who received induction chemotherapy at Tsukuba University Hospital were reviewed. Toxicities during the induction chemotherapy were graded according to the Japanese CTCAE v3.0. Results: Dose reduction was needed in only three patients. The subsequent chemotherapy was started at the planned 3 week interval or within 3 days of postponement in 89% of the treatment cycles. The average relative dose intensity (RDI) of bleomycin was 0.95, while that for etoposide and cisplatin was 0.97. There was no death due to toxicity. The most frequent toxicity was leukopenia (grade 3 in 44% and grade 4 in 55%). Post-chemotherapy diffusion capacity was significantly decreased in 30% of patients. Two patients developed bleomycin-induced pneumonitis, but recovered successfully. Sixteen patients received second line or salvage chemotherapy after BEP, subsequently. The overall 5 year cause-specific survival rate was 85%. Conclusion: BEP with high RDIs is acceptable if combined with modern supportive care, with acceptable toxicity profile in most patients.

KW - BEP

KW - IGCCCG classification

KW - Testicular cancer

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=33748115490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748115490&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyl053

DO - 10.1093/jjco/hyl053

M3 - Article

C2 - 16790450

AN - SCOPUS:33748115490

VL - 36

SP - 425

EP - 431

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 7

ER -